The early detection and management of gestational diabetes mellitus (GDM) present an ideal opportunity to decrease perinatal complications and adverse long-term health outcomes in mothers and their offspring. This review describes the major GDM screening and diagnostic strategies used worldwide, including novel screening and diagnostic methods that are being explored. It highlights the varied screening and diagnostic strategies currently employed in South Africa (SA). The lack of uniform GDM diagnostic criteria and variation in clinical practice hamper early detection and management of GDM, which negatively affects maternal and child health. We recommend that an SA diabetes-in-pregnancy study group, comprising interested obstetricians, physicians, endocrinologists, public health specialists, dieticians and scientists, be established to make evidence-based recommendations on affordable, accessible and applicable GDM screening and diagnostic and management strategies.
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Gestational diabetes mellitus (GDM) is defined as glucose intolerance with onset or first recognition during pregnancy. [1] The prevalence of GDM has significantly increased over the past 20 years, [2] and in 2017 the International Diabetes Federation (IDF) estimated that ~14% of pregnant women are affected by GDM, depending on the diagnostic criteria used and population studied. [3] The World Health Organization (WHO) classifies pre-existing diabetes or newly diagnosed type 1 or type 2 diabetes as severe hyperglycaemia during pregnancy, while GDM represents a milder form of hyperglycaemia that occurs in the latter half of pregnancy and usually resolves after delivery. [4] Without appropriate glucose management, GDM is associated with perinatal complications and an increased risk of future metabolic disease in mothers and their offspring.
The early detection and treatment of GDM are effective in preventing these adverse outcomes; therefore, universal screening and diagnosis of GDM are widely advocated as a strategy to promote appropriate treatment and improve pregnancy outcomes. The oral glucose tolerance test (OGTT) conducted at 24 -28 weeks of gestation is currently considered the gold standard for the diagnosis of GDM. [5] However, the test is cumbersome to conduct, as well as time consuming, expensive and unfeasible in many low-and middle-income countries, resulting in many countries using risk factor-based selective screening. The lack of uniformity in GDM diagnosis and variations in clinical practice hamper its early detection and management, which negatively affect maternal and child health. Therefore, the identification of simple, cost-effective, sensitive and specific biomarkers, which do not require fasting and multiple sampling, may become potential screening and diagnostic tools and have become a major focus in GDM research. This review describes the major GDM screening and diagnostic strategies used worldwide, including novel screening and diagnostic methods that are being explored. It highlights the varied screening and diagnostic strategies currently employed in South Africa (SA). We also discuss challenges associated with these strategies and offer recommendations for future research.
Screening tests
The terms screening and diagnosis are often confusingly used interchangeably. [6] Screening tests identify asymptomatic GDM in apparently healthy pregnant women, facilitating diagnosis and management. [7] A negative screening test obviates the need for the cumbersome OGTT, the gold standard for GDM diagnosis, which is costly and is associated with multiple sampling, nausea and vomiting. Currently, screening for GDM is done by using traditional risk factors, [8] the 50 g glucose challenge test (GCT) or an OGTT. [6] A number of other novel screening tests are being explored, including fasting plasma glucose, [9] glycated haemoglobin (HbA1c), [10] cytokines [11] and molecular biomarkers, [12] which are discussed in more detail below. Screening for traditional risk factors remains the cornerstone of screening strategies in low-and middleincome countries due to costs and ease. However, several studies [8, [13] [14] [15] have reported that risk factors have poor predictive value and fail to identify a large percentage of women with GDM, thus limiting their use. Adam et al. [8] reported that risk factors failed to identify ~10.6% of pregnant women with GDM in SA. The GCT is commonly used to screen for GDM in the USA and involves administering a 50 g glucose load to pregnant women at 24 -28 weeks' gestation, irrespective of fasting. If their 1 h plasma glucose concentrations exceed predetermined cut-off values, usually 7.2 mmol/L or 7.8 mmol/L, they are referred for GDM diagnosis. In 2010, the International Association of Diabetes in Pregnancy Study Groups (IADPSG) advocated for 'no CME screening' or 'universal testing' , where all pregnant women undergo the diagnostic 75 g OGTT at 24 -28 weeks of gestation. [16] Furthermore, the IADPSG decreased the threshold for diagnosing GDM (Table 1) . These recommendations were based on findings from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study that showed a linear correlation between maternal blood glucose concentrations and adverse pregnancy outcomes, even at glucose concentrations previously considered normal. [17] The HAPO study assessed glucose concentrations and pregnancy complications in 23 316 pregnant women across 9 countries; therefore, the IADPSG considered this evidence sufficient to alter the diagnostic criteria for GDM. A few years later, the WHO endorsed the IADPSG universal testing strategy, but remains sceptical owing to poor quality of evidence, increased costs and the possibility of overdiagnosis. [18] Globally, there are no accepted screening criteria for GDM, and universal testing for diagnosing GDM remains the recommended strategy, although its implementation varies across countries and institutions.
Diagnosis
The OGTT is the gold standard for diagnosis of GDM. However, its use is not standardised worldwide and varies according to availability and access of standardised laboratories, resources, cost and GDM risk. The main issues of contention are whether a one-step or two-step procedure, which includes prior screening, is used, the glucose load (75 g or 100 g), duration of test (2 h or 3 h), glucose cut-off values, and whether diagnosis is based on one or two high glucose values. [18] GDM diagnosis has evolved considerably over the years, with older criteria based mainly on managing longterm health outcomes, while more recent criteria focus on adverse perinatal outcomes. The landmark screening and diagnostic criteria for GDM are shown in Fig. 1 . In 1964, O'Sullivan and Mahan [19] proposed a two-step approach, which involved screening with the GCT, followed by a confirmatory 100 g 3 h OGTT in women who tested positive for screening. The National Diabetes Data Group (NDDG) [20] and Carpenter and Coustan [21] revised these criteria in 1979 and 1984, respectively, correcting for the higher glucose concentrations in plasma compared with venous blood that was originally used by O'Sullivan and Mahan. [19] In 1985, the WHO recommended that a 75 g 2 h OGTT be performed to diagnose GDM, using the same thresholds as those for diagnosing diabetes in non-pregnant women. [22] In 1999, the WHO revised their diagnostic criteria for GDM to include impaired glucose tolerance (IGT) and diabetes. [23] The American Diabetes Association (ADA) adopted the Carpenter and Coustan [21] criteria and recommended testing for GDM at 24 -28 weeks' gestation using either a one-O'Sullivan and Mahan [19] 2-step 100 g 3 h OGTT
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step approach with the 100 g OGTT or a two-step procedure with the GCT, followed by a diagnostic 100 g OGTT. [24] In the final report of the Pan American Conference on Diabetes and Pregnancy, the Latin American Diabetes Association (LADA) criteria were proposed for the diagnosis of GDM in selected countries of South America, using a two-step approach with a 75 g 2 h OGTT. [25] In 2010, as previously described, the IADPSG proposed universal testing, where a one-step 75 g 2 h OGTT is conducted for all pregnant women at 24 -28 weeks' gestation. [5] In 2013, the WHO revised their criteria and endorsed those of the IADPGS. [4] The National Institute for Health and Care Excellence (NICE) criteria are based on the WHO 1999 criteria, where GDM is diagnosed as IGT using the 75 g 2 h OGTT. [26] They have not adopted the new recommended IADPSG/WHO 2013 diagnostic criteria, as evidence suggests relatively small differences in clinical outcomes and increased cost implications. [27] Currently, the International Federation of Gynecology and Obstetrics (FIGO) guidelines [1] recommend the use of a glucometer for point-of-care diagnosis of GDM in limited-resource settings due to its low cost, ease of use and ability to diagnose and treat GDM at the earliest possible opportunity. However, a study investigating the performance of the glucometer diagnosis of GDM compared with the gold standard laboratory test showed poor correlation and reproducibility when GDM was diagnosed using the FIGO criteria. [28] Novel screening and diagnostic strategies Glucose Measurement of fasting glucose concentrations has shown promise as a screening [29] and diagnostic test; [8, 30] however, the test requires pregnant women to be in a fasted state and return to the clinic to obtain their laboratory results. [9] Measurement of random glucose and HbA1c levels obviates the need for fasting and has been explored as alternative screening and diagnostic tests. [31] HbA1c, a measurement of the amount of glucose bound to haemoglobin, is currently the gold standard for long-term blood glucose monitoring. However, it is affected by factors such as ethnicity, anaemia, haemodilation or other blood disorders that hamper its accuracy as a diagnostic tool for GDM. [31] [32] [33] Therefore, although these tests are convenient, fast, simple, inexpensive and can be done at point of care, the results are inconsistent, with low sensitivity and specificity, and have been unsuccessful to date.
Other novel strategies investigated in the SA population include the 'breakfast test'-a non-standardised glucose load administered to pregnant women -instead of the OGTT. [34] Because of the variability in carbohydrate content with a non-standardised glucose load, [35] the breakfast test was revised to include a standardised carbohydrate content that is equivalent to the 75 g OGTT. Marais et al. [34] reported a correlation between blood glucose values obtained using the designed breakfast test and values obtained using the OGTT. These and other results suggest that a standardised breakfast test that is more palatable than the OGTT may offer an alternative method for assessing hyperglycaemia during pregnancy. [36] [37] [38] 
Serum proteins
Adaptation to metabolic stress during pregnancy is reflected by changes in the expression of maternal proteins. These proteins are readily detected in plasma or serum and have recently attracted considerable interest as potential screening and diagnostic proteins for GDM. Several studies have reported on the potential of maternal plasma or serum biomarkers, such as adiponectin, sex hormonebinding globulin (SHBG), C-reactive protein (CRP) and glycosylated fibronectin, as biomarkers of GDM.
[39-41] Nanda et al. [39] reported that maternal serum adiponectin and SHBG levels at 11 -13 weeks of gestation were lower in women with GDM than in controls. Similarly, Smirnakis et al. [41] reported lower levels of serum SHBG and higher levels of CRP during the first and second trimesters in pregnant women who subsequently developed GDM. Furthermore, glycosylated fibronectin, adiponectin, CRP and human placental lactogen (hPL) concentrations at 5 -13 weeks of gestation were shown to be associated with GDM. [40] Together, these studies demonstrate that maternal proteins represent a promising first-and secondtrimester screening test to identify women at risk of developing GDM. Further prospective studies are required to investigate the clinical applicability of these biomarkers.
Genetics
Variants in genes regulating glucose homeostasis are increasingly being implicated in the pathogenesis of GDM and thus present candidates for biomarkers of disease pathophysiology. [42] To date, genetic studies have identified 8 genes commonly associated with the development of GDM in ≥2 independent populations. While genetic variants have been identified in other genes associated with GDM, these were only demonstrated in single populations. [12] The genes identified in ≥2 independent populations include transcription factor 7-like 2 (TCF7L2), adiponectin (ADIPOQ), melatonin-receptor 1B gene (MTNR1B), glucokinase (GCK), glucokinase regulator (GCKR), fat mass and obesity-associated (FTO), insulin-receptor substrate 1 (IRS1) and potassium voltage-gated channel subfamily Q member 1 (KCNQ). Due to variation across different populations, further studies are needed to confirm the association between risk alleles and GDM. Further analysis in diverse ethnic groups is required to examine whether these risk variants can be used as biomarkers to predict the development of GDM. Despite the association between genetics and GDM, the important role of the environment in GDM susceptibility is increasingly being recognised.
Epigenetics
Epigenetics is defined as changes in gene expression that occur without changes in the underlying DNA sequence. [43] These changes reflect gene-environment interactions and are increasingly being implicated in the pathophysiology of metabolic diseases. [44, 45] Epigenetic mechanisms include DNA methylation, chromatin and histone modifications, and non-coding RNAs such as microRNAs (miRNAs). DNA methylation is the most widely studied and best characterised epigenetic mechanism, and refers to the addition of a methyl group to the fifth carbon position of a cytosine nucleotide, often leading to transcriptional repression. [46] DNA methylation plays a key role in regulating genes involved in metabolic adaptation during pregnancy, [47] and aberrant DNA methylation is implicated in the pathophysiology of GDM. Altered DNA methylation patterns have been demonstrated in maternal blood, placental tissue and cord blood of GDM-complicated pregnancies, thus supporting its potential as biomarkers. [48] [49] [50] [51] [52] [53] Wu et al. [54] demonstrated that two genes, Hook microtubuletethering protein 2 (HOOK2) and retinol dehydrogenase 12 (RDH12), are differentially methylated in placenta and whole blood of women with GDM. Interestingly, the changes in methylation status of these genes in whole blood occurred prior to the development of GDM, supporting their potential as screening biomarkers of GDM. In a study investigating maternal and cord blood in pregnant women and their offspring, Kang et al. [55] identified 200 genes that were differentially methylated in women with GDM compared with controls. Conversely, our recent study [56] showed no differences in global DNA methylation between pregnant women with GDM and CME those with normoglycaemia in SA. Global DNA methylation is a robust marker for overall genomic methylation; therefore, our failure could be due to subtle methylation differences between GDM and control groups. Perhaps, a more targeted approach using genomewide gene-specific DNA methylation should be considered. Together, these studies show that altered DNA methylation in different biological material plays an important role in the pathophysiology of GDM and offers opportunities as biomarkers.
Another epigenetic mechanism widely explored as a biomarker for GDM, [57] i.e. miRNAs, has been shown to post-transcriptionally regulate genes involved in diverse biological processes, including glucose homeostasis. [58] Placental miRNA expression reflects metabolic adaptation, with aberrant expression observed during GDM. Interestingly, the expression of many of these altered miRNAs is mirrored in serum or plasma, thus offering potential as biomarkers for GDM. Zhao et al. [59] reported that the expression of miR-29a and miR-222, miRNAs that are involved in insulin sensitivity, glucose homeostasis and beta-cell function, are decreased in serum of Chinese women with GDM compared with pregnant women without GDM. Pheiffer et al. [60] similarly reported that the expression of miR-222 is decreased in the serum of SA women with GDM. They also reported the decreased expression of miR-20a, which was a significant predictor of GDM. Conversely, Tagoma et al. [61] reported increased expression of plasma-derived miR-222 in Finnish women with GDM compared with controls, while miR-20a was increased in Chinese women with GDM compared with controls. [62] Furthermore, many studies have demonstrated that placenta-specific miRNAs are altered in pregnancy complications, such as preeclampsia, macrosomia, preterm delivery, pregnancy loss and smallfor-gestational-age babies, which further supports the use of miRNAs as predictive biomarkers for adverse pregnancy outcomes. [63, 64] GDM creates an abnormal intrauterine environment that negatively affects the long-term health of offspring, possibly through in utero programming of epigenetic mechanisms such as DNA methylation and miRNAs. [52, [65] [66] [67] Using genome-wide methylation analysis, Heartle et al. [52] identified 65 CpG sites associated with 52 genes that were differentially methylated in fetal cord blood from GDM and control pregnancies. Of these, 5 candidate genes that play a role in metabolic pathways associated with oxidative damage, cardiovascular complications, glucose and amino-acid metabolisms and adipocyte differentiation were validated. El Hajj et al. [65] showed gene-specific methylation changes in the maternally imprinted MESH gene and the non-imprinted glucocorticoid receptor (NR3C1) gene in both cord blood and placental tissue of GDM groups compared with controls. Recently, altered miRNA expression in the cord blood of offspring was shown to be associated with fetal complications. [66] Tryggestad et al. [67] indicated that 7 miRNAs were upregulated in human umbilical vein endothelial cells from infants born to mothers with GDM. Despite their stability, relative ease of quantification and affordability, DNA methylation and miRNAs present several challenges that hinder their reproducibility across studies. Future research should explore risk-scoring systems that can be used to combine molecular markers with maternal risk indicators to develop a clinical prediction tool for GDM.
Screening and diagnosis in South Africa
The four most common diagnostic criteria used in SA are the IADPSG, NICE, American College of Obstetricians and Gynecologists (ACOG) and WHO 1999 criteria (Table 1 ). In 2017, the Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) endorsed the IADPSG criteria and universal testing of all pregnant women. [68] However, the IADPSG criteria are still being debated, as many clinicians consider these unfeasible in low-and middle-income countries such as SA. Their view is that it leads to overdiagnosis, and places a high demand on costs, workload and resources. Therefore, many local and regional health facilities continue to use risk-factor, selective IADPSG, NICE, ACOG or WHO 1999 criteria (Table 2) . [69] Current perspectives and future recommendations
• Early screening and diagnosis of GDM improve health outcomes.
• Although the OGTT is the gold standard for diagnosis, there is no consensus, and GDM diagnosis is not standardised.
• Novel screening and diagnostic strategies offer potential as biomarkers of GDM, but are yet to achieve clinical applicability. 
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• Future longitudinal studies across SA are required to assess the risks and benefits of diagnostic criteria and pregnancy outcomes.
• Experts are needed to establish and co-ordinate such initiatives and to make evidence-based recommendations on GDM screening and diagnosis.
Conclusions
We have highlighted the varied screening and diagnostic strategies currently employed in SA. Although universal screening and diagnosis of GDM are widely advocated as a strategy to promote appropriate treatment and improve pregnancy outcomes, it is not feasible in many low-and middle-income countries, resulting in many countries using risk factor-based selective screening. The lack of uniform GDM screening and diagnostic criteria and variation in clinical practice negatively affect maternal and child health. There is limited evidence to support one approach over the other. There is a need for longitudinal studies across SA to investigate the association between their diagnostic criteria and pregnancy outcomes, as well as long-term outcomes in mothers and their offspring. We recommend that an SA diabetes-in-pregnancy study group, comprising interested obstetricians, physicians, endocrinologists, public health specialists, dieticians and scientists, be established to co-ordinate such initiatives and to make evidence-based recommendations on GDM screening, diagnosis and management.
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